■ Demo— not a validated GxP system — synthetic data

Affinis

Compound registry

KIN-07 · EGFR mutant-selective — structures, computed properties and batches

Register a compound…
Series
Status
Registered compounds, with their computed properties and mutant-EGFR potency
StructureCompoundSeriesR-groupsFormulaMWcLogPTPSA (Ų)BatchespIC50 mutStatus
NHNNNNOOFAFN-004000BR1 4-Me-piperazin-1-yl · R6 OCH2CH2OMe · R7 FC22H26FN5O2411.53.2962.80—designed
NHNNNNOOONOAFN-004001BR1 4-Me-piperazin-1-yl · R6 OCH2CH2OMe · R7 O(CH2)2-morpholinoC28H38N6O4522.62.8684.517.13tested
NHNNNNOOClAFN-004002BR1 4-Me-piperazin-1-yl · R6 OCH2CH2OMe · R7 ClC22H26ClN5O2427.93.8062.80—designed
NHNNNNOOOHAFN-004003BR1 4-Me-piperazin-1-yl · R6 OCH2CH2OMe · R7 OHC22H27N5O3409.52.8683.00—designed
NHNNNNONOAFN-004004BR1 4-Me-piperazin-1-yl · R6 O(CH2)3-morpholino · R7 HC26H34N6O2462.63.2366.00—designed
NHNNNNONOOAFN-004005BR1 4-Me-piperazin-1-yl · R6 O(CH2)3-morpholino · R7 OMeC27H36N6O3492.63.2375.217.21tested
NHNNNNONOOAFN-004006BR1 4-Me-piperazin-1-yl · R6 O(CH2)3-morpholino · R7 OEtC28H38N6O3506.63.6375.20—designed
NHNNNNONOOOAFN-004007BR1 4-Me-piperazin-1-yl · R6 O(CH2)3-morpholino · R7 OCH2CH2OMeC29H40N6O4536.73.2584.50—designed
NHNNNNONOFAFN-004008BR1 4-Me-piperazin-1-yl · R6 O(CH2)3-morpholino · R7 FC26H33FN6O2480.63.3766.00—designed
NHNNNNONOONOAFN-004009BR1 4-Me-piperazin-1-yl · R6 O(CH2)3-morpholino · R7 O(CH2)2-morpholinoC32H45N7O4591.82.9487.70—designed
NHNNNNONOClAFN-004010BR1 4-Me-piperazin-1-yl · R6 O(CH2)3-morpholino · R7 ClC26H33ClN6O2497.03.8866.00—designed
NHNNNNONOOHAFN-004011BR1 4-Me-piperazin-1-yl · R6 O(CH2)3-morpholino · R7 OHC26H34N6O3478.62.9386.20—designed
NHNNNNNHOAFN-004012BR1 4-Me-piperazin-1-yl · R6 acrylamido · R7 HC22H24N6O388.53.2573.417.66tested
NHNNNNNHOOAFN-004013BR1 4-Me-piperazin-1-yl · R6 acrylamido · R7 OMeC23H26N6O2418.53.2682.60—designed
NHNNNNNHOOAFN-004014BR1 4-Me-piperazin-1-yl · R6 acrylamido · R7 OEtC24H28N6O2432.53.6582.60—designed
NHNNNNNHOOOAFN-004015BR1 4-Me-piperazin-1-yl · R6 acrylamido · R7 OCH2CH2OMeC25H30N6O3462.63.2791.917.75tested
NHNNNNNHOFAFN-004016BR1 4-Me-piperazin-1-yl · R6 acrylamido · R7 FC22H23FN6O406.53.3973.40—designed
NHNNNNNHOONOAFN-004017BR1 4-Me-piperazin-1-yl · R6 acrylamido · R7 O(CH2)2-morpholinoC28H35N7O3517.62.9695.10—designed
NHNNNNNHOClAFN-004018BR1 4-Me-piperazin-1-yl · R6 acrylamido · R7 ClC22H23ClN6O422.93.9073.417.98tested
NHNNNNNHOOHAFN-004019BR1 4-Me-piperazin-1-yl · R6 acrylamido · R7 OHC22H24N6O2404.52.9693.60—designed
NHNNSOOAFN-004020BR1 SO2Me · R6 H · R7 HC15H13N3O2S299.42.7872.00—designed
NHNNSOOOAFN-004021BR1 SO2Me · R6 H · R7 OMeC16H15N3O3S329.42.7981.20—designed
NHNNSOOOAFN-004022BR1 SO2Me · R6 H · R7 OEtC17H17N3O3S343.43.1881.20—designed
NHNNSOOOOAFN-004023BR1 SO2Me · R6 H · R7 OCH2CH2OMeC18H19N3O4S373.42.8090.40—designed
NHNNSOOFAFN-004024BR1 SO2Me · R6 H · R7 FC15H12FN3O2S317.42.9272.00—designed
NHNNSOOONOAFN-004025BR1 SO2Me · R6 H · R7 O(CH2)2-morpholinoC21H24N4O4S428.52.4993.70—designed
NHNNSOOClAFN-004026BR1 SO2Me · R6 H · R7 ClC15H12ClN3O2S333.83.4372.00—designed
NHNNSOOOHAFN-004027BR1 SO2Me · R6 H · R7 OHC15H13N3O3S315.42.4892.215.73tested
NHNNSOOOAFN-004028BR1 SO2Me · R6 OMe · R7 HC16H15N3O3S329.42.7981.20—designed
NHNNSOOOOAFN-004029BR1 SO2Me · R6 OMe · R7 OMeC17H17N3O4S359.42.7990.416.51tested
NHNNSOOOOAFN-004030BR1 SO2Me · R6 OMe · R7 OEtC18H19N3O4S373.43.1890.40—designed
NHNNSOOOOOAFN-004031BR1 SO2Me · R6 OMe · R7 OCH2CH2OMeC19H21N3O5S403.52.8199.60—designed
NHNNSOOOFAFN-004032BR1 SO2Me · R6 OMe · R7 FC16H14FN3O3S347.42.9281.20—designed
NHNNSOOOONOAFN-004033BR1 SO2Me · R6 OMe · R7 O(CH2)2-morpholinoC22H26N4O5S458.52.50102.90—designed
NHNNSOOOClAFN-004034BR1 SO2Me · R6 OMe · R7 ClC16H14ClN3O3S363.83.4481.20—designed
NHNNSOOOOHAFN-004035BR1 SO2Me · R6 OMe · R7 OHC16H15N3O4S345.42.49101.40—designed
NHNNSOOOAFN-004036BR1 SO2Me · R6 OEt · R7 HC17H17N3O3S343.43.1881.216.48tested
NHNNSOOOOAFN-004037BR1 SO2Me · R6 OEt · R7 OMeC18H19N3O4S373.43.1890.40—designed
NHNNSOOOOAFN-004038BR1 SO2Me · R6 OEt · R7 OEtC19H21N3O4S387.53.5790.40—designed
NHNNSOOOOOAFN-004039BR1 SO2Me · R6 OEt · R7 OCH2CH2OMeC20H23N3O5S417.53.2099.60—designed
NHNNSOOOFAFN-004040BR1 SO2Me · R6 OEt · R7 FC17H16FN3O3S361.43.3181.20—designed
NHNNSOOOONOAFN-004041BR1 SO2Me · R6 OEt · R7 O(CH2)2-morpholinoC23H28N4O5S472.62.89102.90—designed
NHNNSOOOClAFN-004042BR1 SO2Me · R6 OEt · R7 ClC17H16ClN3O3S377.93.8381.20—designed
NHNNSOOOOHAFN-004043BR1 SO2Me · R6 OEt · R7 OHC17H17N3O4S359.42.88101.40—designed
NHNNSOOOOAFN-004044BR1 SO2Me · R6 OCH2CH2OMe · R7 HC18H19N3O4S373.42.8090.416.49tested
NHNNSOOOOOAFN-004045BR1 SO2Me · R6 OCH2CH2OMe · R7 OMeC19H21N3O5S403.52.8199.60—designed
NHNNSOOOOOAFN-004046BR1 SO2Me · R6 OCH2CH2OMe · R7 OEtC20H23N3O5S417.53.2099.60—designed
NHNNSOOOOOOAFN-004047BR1 SO2Me · R6 OCH2CH2OMe · R7 OCH2CH2OMeC21H25N3O6S447.52.83108.90—designed
NHNNSOOOOFAFN-004048BR1 SO2Me · R6 OCH2CH2OMe · R7 FC18H18FN3O4S391.42.9490.40—designed
NHNNSOOOOONOAFN-004049BR1 SO2Me · R6 OCH2CH2OMe · R7 O(CH2)2-morpholinoC24H30N4O6S502.62.51112.10—designed

Properties calculated with RDKit offline, not at runtimeSubstructure: our own screen fingerprint, then VF2 matching — no RDKit at runtimepIC50 mut = mean of approved fits on ASY-EGFR-TM-03